Clinical Trials Logo

Clinical Trial Summary

Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration. To date, there are only a few cases reporting ocular and orbital manifestations of mastocytosis. Our prospective, interventional and single-center study consist in describing the ocular functional manifestations and ocular surface abnormalities of patients with systemic and cutaneous mastocytosis.


Clinical Trial Description

Patient with systemic or cutaneous mastocytosis will be included in the study. Data about organ involvement of mastocytosis will be collected. Participants will be screened with a medical and eye disease history. They will also have an eye exam. Participants will provide a tears sample. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04978740
Study type Interventional
Source Poitiers University Hospital
Contact
Status Completed
Phase N/A
Start date July 30, 2021
Completion date September 3, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05449444 - Masitinib for the Treatment of Severe Mast Cell Activation Syndrome Phase 2
Terminated NCT05652907 - Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) Phase 2
Completed NCT03406325 - Mast Cell Activation Test in Allergic Disease